Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Welcome to OncLive On Air^®! I’m your host today, Caroline Seymour.

OncLive On Air^® is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive^® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Janssen, we had the pleasure of speaking with Saad Z. Usmani, MD, MBA, FACP, about the use of bispecific antibodies in relapsed/refractory multiple myeloma. Dr Usmani is a hematologist-oncologist at Memorial Sloan Kettering Cancer Center in New York, New York.

Between October 25, 2022, and August 14, 2023, the FDA approved 3 bispecific antibodies for the treatment of patients with relapsed/refractory multiple myeloma who have previously received at least 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Each indication received accelerated approval from the FDA based on objective response rate data from phase 2 trials.

These off-the-shelf agents targeting BCMA and GPRC5D join an already crowded landscape. However, Usmani explained that with the withdrawal of the BCMA-directed antibody-drug conjugate belantamab mafodotin-blmf (Blenrep) in November 2022, these off-the-shelf agents will have a role to play in the treatment of patients with heavily pretreated disease who cannot afford to wait for CAR T-cell therapy. Real-world data will also help inform optimal treatment sequencing, Usmani noted, adding that the field cannot count on loss of BCMA to direct subsequent treatment decisions.

In our exclusive interview, Dr Usmani discussed the integration of elranatamab-bcmm (Elrexfio), talquetamab-tgvs (Talvey), and teclistamab-cqyv (Tecvayli) into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air^®, sponsored by Janssen. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air^®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air^®.

*OncLive On Air^® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.